Navigation Links
SemBioSys announces 2007 third quarter results
Date:11/1/2007

- Canadian Biotechnology Company demonstrates the technical feasibility of

a second high-value biopharmaceutical in safflower -

TSX symbol: SBS

CALGARY, Nov. 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its 2007 third quarter operational and financial results.

Highlights

- Successfully developed commercially viable levels of both

apolipoprotein AI (Apo AI) Milano variant and, subsequent to the end

of the quarter, native Apo AI accumulation in safflower seed.

- Continued the preclinical work necessary to submit an Investigational

New Drug application (IND) to the United States Food and Drug

Administration (FDA) in early 2008 to initiate a Phase II trial for

safflower-produced insulin.

- Established Botaneco, a separate business unit dedicated to the

commercialization of SemBioSys' oilbody products for the cosmetics,

personal care and prescription topical dermatology markets.

- Commissioned the Company's commercial scale manufacturing operation

for the Botaneco business and subsequent to the end of the quarter

launched Hydresia(TM), Botaneco's first branded line of oilbody-based

ingredients.

- Obtained $2.4 million in non-dilutive development funding from AVAC

Ltd. to develop the Botaneco business, subsequent to quarter end.

- Entered into an agreement to complete a private placement financing

for total gross proceeds of approximately $9,568,000, of which

$6,500,000 was completed on a bought deal basis, subsequent to

quarter end.

- Appointed Mr. Ian S. Brown to the Board of Directors, subsequent to

quarter end. Mr. Brown is an independent businessman with ove
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... of Surrey have discovered how the receptors responsible for ... , The new study, published today in The ... in turn regulates the cycle of all cells in ... the local biological clock and its control are weakened ... in bladder physiology and ageing. , While ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... of the interesting and challenging endeavors as the ... highly impervious properties to the foreign substances. Ocular ... possibility of self medication and minimal use of ... molecular weight drugs and provides specific targeting within ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies ... company developing first in class collagenase-based products marketed ... CCH) in the U.S. and XIAPEX ® ... results from a randomized, double-blind Phase 2a study ... or edematous fibrosclerotic panniculopathy. The results showed that ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... N.Y., Jan. 31 Mr. Donald Fresne, ... that the company has recently,obtained from Harvard ... cover certain technologies related to cancer therapy ... developed jointly,by scientists in the Laboratory for ...
... VCs face more competition from private ... equity and hedge ... their investments to the greentech and biotech industries in the,coming year, ... a recent survey by the U.S. audit, tax and advisory,firm KPMG ...
... 31 Schering-Plough,Corporation (NYSE: SGP ) today ... has accepted the Peg-IFN (peginterferon alfa-2b),supplemental Biologics License ... status for the adjuvant treatment of patients with,Stage ... agency,in the fall of 2007., The Priority ...
Cached Biology Technology:Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 2Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... University have developed a novel and versatile modeling strategy ... creating new materials as well as for studying polyelectrolytes, ... us to model much larger and more complex polyelectrolyte ... Nan Li, lead author of a paper on the ... of Materials Science and Engineering. "This is a big ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... In 2007, researchers of the Max Planck Institute ... in exploratory behaviour in great tits. Birds with a ... (DRD4 gene) showed stronger novelty seeking and exploration behaviour ... tested and found in a lab-raised group of birds. ...
... , Some animals, it seems, are going on a ... these are reactions to rapidly rising temperatures due to ... Aviv University,s Department of Zoology, who has been measuring ... areas where climate change is most extreme. , Changes ...
... with anorexia nervosa, paradoxically, have strikingly high levels of fat ... Their findings, based on MRI imaging of the knees of ... same age, appear in the February issue of the ... that an emaciated young woman with almost no subcutaneous fat ...
Cached Biology News:Great tits: birds with character 2Animals cope with climate change at the dinner table 2Anorexics found to have excess fat-- in their bone marrow 2
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
This thermal printer, 120 V, provides a permanent record of the preprogrammed method and run data for the PROTEAN IEF cell. Includes cable and power adaptor....
... iCycler thermal cycler with 384-well reaction module ... applications. It is equipped with an interchangeable, ... features algorithm temperature monitoring and control and ... sample volumes. It includes the iCycler base ...
Biology Products: